PMA submissions up almost 60% to 70 applications in FY 1997 - - ODE annual report.
This article was originally published in The Gray Sheet
PMA SUBMISSIONS INCREASE NEARLY 60% TO 70 APPLICATIONS IN FY 1997, according to the annual report released by FDA's Office of Device Evaluation the week of Feb. 2. The 70 premarket approval applications received in fiscal year 1997 (ended Sept. 31) compares to 44 submitted in 1996 and is the most submitted since 1991. Of the 74 PMA-related filing decisions made during FY 1997, over 75% (58) were accepted for filing, the highest percentage in over 10 years. Nearly the same percentage of PMAs (72%, or 48) were approved, and 14 PMAs (21%) were deemed approvable.
You may also be interested in...
Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.